Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1476-5608
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer ; volume:23 ; number:4 ; day:13 ; month:5 ; year:2020 ; pages:680-688 ; date:12.2020
Prostate cancer and prostatic diseases ; 23, Heft 4 (13.5.2020), 680-688, 12.2020

Urheber
Shore, Neal
Higano, Celestia S.
George, Daniel J.
Sternberg, Cora N.
Saad, Fred
Tombal, Bertrand
Miller, Kurt
Kalinovsky, Jan
Jiao, XiaoLong
Tangirala, Krishna
Sartor, Oliver
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1038/s41391-020-0236-0
URN
urn:nbn:de:101:1-2020122122005570644673
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:29 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Shore, Neal
  • Higano, Celestia S.
  • George, Daniel J.
  • Sternberg, Cora N.
  • Saad, Fred
  • Tombal, Bertrand
  • Miller, Kurt
  • Kalinovsky, Jan
  • Jiao, XiaoLong
  • Tangirala, Krishna
  • Sartor, Oliver
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone

Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”

Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan

Verbundene Objekte